Menu:
Our Portfolio
Our intellectual property portfolio represents six years of research and development and includes:
- Impressive efficacy results in preclinical and clinical studies
- Safety
- Potential to address large markets
Drugs in Development
MS-191112 (Anilixier®)
MS-191112 is proprietary botanical extract with very potent anti-inflammatory and anti-infective activities. MS-191112 is currently undergoing a clinical trial in bovine mastitis. Preliminary results show exceptional efficacy results rivaling conventional antibiotic regimens. A summary of the results can be found here.
LS-051136 (Wulfenin®)
LS-051136 is a newly discovered defensin with significant antibacterial activity against a variety of gram-positive and gram-negative organisms.
EH-010107
EH-010107 is an advanced botanical formulation possessing very promissing immunomodulatory properties.